SCHEMBL8301608

SCHEMBL8301608

C1CN(C[C@@H]2CN2)CCN1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 5/20 0.40
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SIGMAR1 Q99720 3/20 0.34
RAD52 P43351 1/20 0.34
HSD17B10 Q99714 1/20 0.32
CHRM5 P08912 2/20 0.32
CHRM3 P20309 2/20 0.32
HRH3 Q9Y5N1 2/20 0.31
MEN1 O00255 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
ADRA2C P18825 1/20 0.31
CCR2 P41597 1/20 0.31
CXCL12 P48061 1/20 0.31
BLM P54132 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5892042 1.00 CXCR4 (0.40) CXCR4POLBSMN1; SMN2SIGMAR1RAD52
SCHEMBL8658731 0.87 CXCR4 (0.50) CXCR4POLBSMN1; SMN2SIGMAR1RAD52
SCHEMBL6282596 0.84
SCHEMBL9191635 0.79 CXCR4 (0.68) CXCR4SMN1; SMN2SIGMAR1HRH3MEN1
SCHEMBL24684844 0.78 HTR1A (0.43) CXCR4SIGMAR1RAD52CHRM5CHRM3
SCHEMBL15558472 0.78 HTR1A (0.43) CXCR4SIGMAR1RAD52CHRM5CHRM3
SCHEMBL7840193 0.77 ADRA2C (0.48) CHRM5HRH3MEN1ADRA2CKMT2A
SCHEMBL5892038 0.76 CXCR4 (0.41) CXCR4HRH3
SCHEMBL2578794 0.75 POLB (0.37) CXCR4POLBSMN1; SMN2SIGMAR1RAD52
SCHEMBL27980711 0.73 CXCR4 (0.36) CXCR4POLBSMN1; SMN2SIGMAR1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952842-A2 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 1999-11-03 EP disclosed
WO-1997038664-A2 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-10-23 WO disclosed